Sarepta Therapeutics, Inc.
NASDAQ:SRPTBiotechnology
+$0.29 today
- Market cap
- $1.56B
- Beta
- 0.20
- P/E (TTM)
- 27.8
- EPS (TTM)
- $0.62
Volume 1.86M
Average 3.08M
SRPT Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Sarepta Therapeutics, Inc.NASDAQ: SRPT
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $3.42M, compared with -$57.38M a year earlier. Trailing-twelve-month accounts receivables was $264.55M.
Context
- Accounts receivables amounted to 9.3% of revenue in FY2025, down 1.3 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $3.42M or moves back toward the trailing-twelve-month quarterly average of $66.14M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 203.76M USD
- Year-over-year change
- +201.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 203.76M | +201.0% |
| FY2024 | 2024-12-31 | (201.66M) | -8.6% |
| FY2023 | 2023-12-31 | (185.7M) | -201.3% |
| FY2022 | 2022-12-31 | (61.64M) | -19.3% |
| FY2021 | 2021-12-31 | (51.65M) | — |
Accounts Receivables vs competitors
How SRPT compares with its peers on the latest reported figures
- SRPT's LTM Mar 2026 accounts receivables of $264.55M is the 2nd largest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of +194.3% is the 2nd highest of 7, against a peer median of -54.4%.
- Accounts receivables amounts to 12.1% of revenue for SRPT, versus a peer median of 4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $357.64M | +48.4% | +99.1% | 7.4% | |
| LTM Mar 2026 | $264.55M | +194.3% | — | 12.1% | |
| LTM Sep 2026 | $63.73M | -14.2% | -10.4% | 6.6% | |
| LTM Jun 2026 | $44.38M | -720.6% | -40.6% | 4.4% | |
| LTM Mar 2026 | $1.37M | -94.7% | -18.2% | 2.1% | |
| LTM Mar 2026 | $177.78K | +291.8% | — | 0.2% | |
| LTM Mar 2026 | $59.83K | -100.0% | — | — | |
| LTM Jun 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding SRPT) | $0 | -54.4% | -14.3% | 4.4% | |
Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (418.78M) | (703.49M) | (535.98M) | 235.24M | (713.41M) |
| Depreciation & Amortization | 38.02M | 41.86M | 44.4M | 37.72M | 44.52M |
| Deferred Income Tax | 15.81M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 113.94M | 233.02M | 182.51M | 184.3M | 123.4M |
| Change in Working Capital | (98.17M) | (39.47M) | (481.09M) | (716.61M) | 78.04M |
| Accounts Receivables | (51.65M) | (61.64M) | (185.7M) | (201.66M) | 203.76M |
| Inventory | (83.77M) | (50.78M) | (147.71M) | (395.17M) | (301.09M) |
| Accounts Payables | 23.3M | 147.57M | (50.14M) | 110.65M | 104.27M |
| Other Working Capital | 13.96M | (74.62M) | (97.54M) | (230.42M) | 71.11M |
| Other Non-Cash Items | (94M) | 142.73M | 289.16M | 53.56M | 261.98M |
| Operating Cash Flow | (443.17M) | (325.35M) | (500.99M) | (205.79M) | (205.48M) |
| Capital Expenditures | (38.49M) | (32.25M) | (87.35M) | (146.96M) | (101.97M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (29.99M) | (1.94B) | (2.05B) | (1.1B) | (44.66M) |
| Sales of Investments | 466M | 923.22M | 1.87B | 2B | 469.97M |
| Other Investing Activities | 97.89M | (1.43M) | 90.76M | (10M) | (253.7M) |
| Investing Cash Flow | 495.41M | (1.05B) | (165.8M) | 755.56M | 69.64M |
| Debt Repayment | 0 | 304.17M | 0 | (68K) | (162.59M) |
| Common Stock Issued | 548.53M | 0 | 0 | 0 | 36.32M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (25.01M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 13.04M | (71.66M) | 125M | 124.87M | (17.06M) |
| Financing Cash Flow | 561.57M | 232.51M | 125M | 124.81M | (168.34M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 613.81M | (1.14B) | (541.79M) | 674.58M | (304.18M) |
| Free Cash Flow | (481.66M) | (357.6M) | (588.34M) | (352.74M) | (307.45M) |
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
Intrinsic Alpha fair value
Locked
Current Price
$14.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.